12:00 AM
 | 
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AzaSite Plus: Phase III data

Top-line data from the double-blind, U.S. Phase III DOUBle trial in 907 patients with moderate to severe blepharitis showed that AzaSite Plus and DexaSite each missed the primary endpoint of complete resolution of all clinical signs and symptoms of blepharitis at day 15 vs. AzaSite and DuraSite vehicle, respectively. Specifically, the proportion of patients achieving a disease severity score of 0 points at day 15 was 8.4% for AzaSite Plus, 5.8% for DexaSite, 5.3% for AzaSite...

Read the full 360 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >